| COS Unique Id: |
106769 |
| Title: |
Development of Assays for High-Throughput Drug Screening (R01) |
| Sponsor: |
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
|
| Sponsor Type: |
Federal, U.S. |
| Deadline: |
June 5, 2008
October 5, 2008
February 5, 2009
|
| Deadline Note: |
This program announcement expires on May 2, 2010. |
| Amount Note: |
This program will use the R01 grant mechanism.
Because the nature and scope of the proposed research will vary from
application to application, it is anticipated that the size and
duration of each award will also vary. Applicants may request a project
period of up to three years. |
| Eligibility: |
Applications may be submitted by domestic or
foreign, for-profit or nonprofit, public or private institutions, such
as universities, colleges, hospitals, and laboratories; units of state
and local government; and eligible agencies of the federal government. |
| Citizenship or Residency: |
Unrestricted
|
| Activity Location: |
Unrestricted
|
| Requirements: |
Small Business
Ph.D./M.D./Other Professional
Commercial
Government
Nonprofit
Academic Institution
|
| Abstract: |
The overall goal of the Molecular Libraries
Initiative, part of the National Institutes of Health (NIH) Roadmap for
Medical Research, is to offer public sector researchers opportunities
to screen small molecules with the high-throughput chemical screening
(HTS) methods commonly used by the private sector to develop
therapeutic agents. The purpose of this program is to support the
development of innovative assays that may ultimately be adapted for
automated screening. The assay should aim to identify new tools for
basic research or promising new avenues for therapeutics development,
especially in areas related to the missions of the participating
institutes (National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK), National Cancer Institute (NCI), National Institute
of Allergy and Infectious Diseases NIAID), and National Institute of
Mental Health (NIMH)).
Relevant topics include but are not limited to,
-
assays for molecular chaperones or molecules that improve the
post-translational targeting, folding, or assembly of proteins,
especially involving mutant proteins responsible for inborn errors of
metabolism, cancers, or other rare diseases;
- screens involving
immunological targets, especially in the context of research that
focuses on autoimmune diseases or areas where specific antibodies
stimulate or inhibit relevant processes;
- model organism-based
assays, such as those using bacteria, yeast, Drosophila, C. elegans,
zebrafish, etc., that have relevance to the research areas of the
sponsoring institutes, with particular interest in projects that aim to
significantly improve on the automation of imaging analysis and whole
organism handling;
- assays for compounds that identify
multi-protein signaling complexes, or that modify the function of
signaling complexes, regulatory networks, and sorting machinery;
-
assays to identify highly specific molecular markers that might be
useful for identifying or tracking a particular cell or function;
- biochemical or cell-based assays of activity, behavior, or interaction of proteins and other molecules of interest;
- assays of cellular or molecular phenotypes;
-
modulation of expression of genes of interest, including effects on
transcription factors, transcription, translation, or RNA splicing;
- assays that biochemically incorporate an entire metabolic or macromolecular biosynthetic pathway from an organism;
- whole cell assays that employ engineered cells rendered hypersensitive to a targeted pathway; and
- assay projects that aim to test the feasibility of simultaneous, multiplexed readouts of related target: ligand interactions. |
| Contact Address: |
Interested applicants should contact the relevant institute listed in Section VII. Agency Contacts of the URL. |
| Contact Country: |
United States |
| URL for more information: |
http://grants1.nih.gov/grants/guide/pa-files/PA-07-320.html |
| Date Last Revised: |
March 4, 2008 |
| URL from COS to Bookmark this record: |
http://fundingopps.cos.com/cgi-bin/getRec?id=106769 |
| Keywords: |
Biomarkers
Cell Biology
Phenotype
Protein Structure
Proteins and Macromolecules
|
| Sponsor Reference No: |
PA-07-320 |
| Funding Type: |
Research
|
| COS Unique Id: |
106956 |
| Title: |
Development of Animal Models and Related Biological Materials for Research (R21) |
| Sponsor: |
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Center for Research Resources (NCRR)
|
| Sponsor Type: |
Federal, U.S. |
| Deadline: |
June 16, 2008
October 16, 2008
February 16, 2009
|
| Deadline Note: |
This program will expire on May 8, 2010. |
| Upper Amount: |
$275,000 |
| Amount Note: |
This program will use the R21 grant mechanism. The
total project period for an application submitted in response to this
funding opportunity may not exceed two years. Although the size of
award may vary with the scope of research proposed, it is expected that
applications will stay within the budgetary guidelines for an
exploratory/developmental project; direct costs are limited to $275,000
over an R21 two-year period. |
| Eligibility: |
Applications may be submitted by domestic or
foreign, for-profit or nonprofit organizations and public or private
institutions, such as universities, colleges, hospitals, and
laboratories; units of state and local governments; regional
organizations; and faith-based or community-based organizations. Small
businesses are not eligible for this opportunity. |
| Citizenship or Residency: |
Unrestricted
|
| Activity Location: |
Unrestricted
|
| Requirements: |
Ph.D./M.D./Other Professional
Commercial
Government
Nonprofit
Academic Institution
|
| Abstract: |
The translation of basic biomedical knowledge to
prevention or new treatments often requires the use of animals as
models for human disease. Such models provide invaluable insight in the
cause and biology of diseases, diagnoses, and therapeutics in humans.
Strength in biomedical research relates to the development and the
improvement of a particular animal model system and continued
development of tools related to existing model systems which make those
models more useful or more widely applicable. Although much progress
has been made in this area, further studies are needed to develop and
broaden the utility of models and related research materials for
biomedical research.
The objective of this announcement issued
by the National Center for Research Resources (NCRR) is to stimulate
novel areas of investigation related to laboratory animal science and
medicine and model systems that do not fall within the categorical
interest of a single institute or center (IC) of the National
Institutes of Health (NIH). Categories and examples of such research
include the following:
1. Animal Models - Develop and characterize
natural and genetically modified animal models for human biology and
disease. Model systems include both mammalian and nonmammalian species,
as well as cell culture systems and integrative computer models.
2.
Reproductive Biology - Improve methods for producing transgenic
knockout and genetically identical animals and for cryopreservation of
biological materials, including germ plasm.
3. Fundamental Biology
of Animal Systems - Perform investigations of basic aspects of animal
models, including but not limited to, animal genetics, physiology,
behavior, nutrition, and identification and characterization of
nontraditional species for research.
4. Regenerative Medicine -
Develop animal models for gene and cellular-based therapies of disease;
isolate and characterize animal stem cells.
5. Animal Disease -
Detect and characterize diseases that may interfere with research and
compromise animal welfare; support studies related to development of
vaccines and of animals genetically resistant to disease.
Applications
for R21 awards should describe projects distinct from those supported
through the traditional R01 mechanism. For example, long-term projects,
or projects designed to increase knowledge in a well-established area,
will not be considered for R21 awards. Applications submitted under
this mechanism should be exploratory and novel. These studies should
break new ground or extend previous discoveries toward new directions
or applications. Projects of limited cost or scope that use widely
accepted approaches and methods within well-established fields are
better suited for the R03 small grant mechanism. |
| Contact Name: |
Jean Richelsen |
| Contact Address: |
Office of Grants Management, NCRR
6701 Democracy Boulevard
Room 1052 MSC 4874 |
| Contact City: |
Bethesda |
| Contact State: |
Maryland |
| Contact Zip: |
20892-4874 |
| Contact Country: |
United States |
| Contact Phone: |
+1 (301) 435-0844 |
| Contact Fax: |
+1 (301) 480-3777 |
| Contact Email: |
richelsj@mail.nih.gov |
| URL for more information: |
http://grants1.nih.gov/grants/guide/pa-files/PA-07-336.html |
| Date Last Revised: |
March 6, 2008 |
| URL from COS to Bookmark this record: |
http://fundingopps.cos.com/cgi-bin/getRec?id=106956 |
| Keywords: |
Animal Models
|
| Sponsor Reference No: |
PA-07-336 |
| Funding Type: |
Research
|
| COS Unique Id: |
107011 |
| Title: |
HIV Treatment Adherence Research (R01) |
| Sponsor: |
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
|
| Sponsor Type: |
Federal, U.S. |
| Deadline: |
June 5, 2008
October 5, 2008
February 5, 2009
|
| Deadline Note: |
This program announcement expires on January 8, 2010. |
| Amount Note: |
This program will use the R01 grant mechanism.
Because the nature and scope of the proposed research will vary from
application to application, it is anticipated that the size and
duration of each award will also vary. |
| Eligibility: |
Applications may be submitted by domestic or
foreign, for-profit or nonprofit, public or private institutions, such
as universities, colleges, hospitals, and laboratories; units of state
and local government; and regional organizations. |
| Citizenship or Residency: |
Unrestricted
|
| Activity Location: |
Unrestricted
|
| Requirements: |
Small Business
Ph.D./M.D./Other Professional
Commercial
Government
Nonprofit
Academic Institution
|
| Abstract: |
This funding opportunity announcement (FOA),
sponsored by the National Institute of Mental Health (NIMH), National
Institute on Drug Abuse (NIDA), and National Institute of Nursing
Research (NINR), calls for research to advance the scientific
understanding of HIV treatment adherence and to enhance and expand
available intervention strategies to promote, improve, and sustain
adherence. The overarching emphasis is on the development of innovative
behavioral and structural adherence interventions that could be rapidly
translated into clinical practice, community venues, and public health
policy within domestic and international settings. Any descriptive
studies should therefore be undertaken with the aim of informing the
mechanisms of adherence interventions. Interventions may target patient
adherence to antiretroviral medications or other aspects of HIV
treatment that can be shown to affect patient outcomes and public
health (e.g., linkage to primary care, medical appointment attendance,
and service utilization). Investigators are encouraged to consider
incorporation of clinical outcomes (e.g., viral load, CD4 T-cell count,
drug resistance) into intervention trials when feasible and
scientifically appropriate. Studies are also needed that will advance
knowledge of effective approaches for promoting the dissemination,
adoption, and sound implementation of tested adherence interventions. A
well-articulated and empirically based conceptual framework is
essential for all applications solicited under this announcement.
Approaches based on basic behavioral and social scientific principles
such as cognition, emotion, decision-making, motivation, social
interaction, structural factors, and cultural context are invited.
Proposals for interdisciplinary and community-collaborative research
addressing HIV treatment adherence are particularly encouraged. |
| Contact Address: |
Interested applicants should contact the relevant institute listed in "Section VII. Agency Contacts" of this announcement. |
| Contact Country: |
United States |
| URL for more information: |
http://grants1.nih.gov/grants/guide/pa-files/PA-07-338.html |
| Date Last Revised: |
March 5, 2008 |
| URL from COS to Bookmark this record: |
http://fundingopps.cos.com/cgi-bin/getRec?id=107011 |
| Keywords: |
AIDS Therapy
HIV
Medical Treatment
|
| Sponsor Reference No: |
PA-07-338 |
| Funding Type: |
Research
|
| COS Unique Id: |
107012 |
| Title: |
HIV Treatment Adherence Research (R03) |
| Sponsor: |
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
|
| Sponsor Type: |
Federal, U.S. |
| Deadline: |
June 16, 2008
October 16, 2008
February 16, 2009
|
| Deadline Note: |
This program announcement expires on January 8, 2010. |
| Upper Amount: |
$100,000 |
| Amount Note: |
This program will use the R03 grant mechanism. A
project period of up to two years and a budget for direct costs of up
to two $25,000 modules, or $50,000 per year, may be requested (i.e., a
maximum of $100,000 over two years in four modules of $25,000 each). |
| Eligibility: |
Applications may be submitted by domestic or
foreign, for-profit or nonprofit, public or private institutions, such
as universities, colleges, hospitals, and laboratories; units of state
and local government; and regional organizations. |
| Citizenship or Residency: |
Unrestricted
|
| Activity Location: |
Unrestricted
|
| Requirements: |
Small Business
Ph.D./M.D./Other Professional
Commercial
Government
Nonprofit
Academic Institution
|
| Abstract: |
This funding opportunity announcement (FOA),
sponsored by the National Institute of Mental Health (NIMH) and the
National Institute on Drug Abuse (NIDA), calls for research to advance
the scientific understanding of HIV treatment adherence and to enhance
and expand available intervention strategies to promote, improve, and
sustain adherence. The overarching emphasis is on the development of
innovative behavioral and structural adherence interventions that could
be rapidly translated into clinical practice, community venues, and
public health policy within domestic and international settings. Any
descriptive studies should therefore be undertaken with the aim of
informing the mechanisms of adherence interventions. Interventions may
target patient adherence to antiretroviral medications or other aspects
of HIV treatment that can be shown to affect patient outcomes and
public health (e.g., linkage to primary care, medical appointment
attendance, and service utilization). Investigators are encouraged to
consider incorporation of clinical outcomes (e.g., viral load, CD4
T-cell count, drug resistance) into intervention trials when feasible
and scientifically appropriate. Studies are also needed that will
advance knowledge of effective approaches for promoting the
dissemination, adoption, and sound implementation of tested adherence
interventions. A well-articulated and empirically based conceptual
framework is essential for all applications solicited under this
announcement. Approaches based on basic behavioral and social
scientific principles such as cognition, emotion, decision-making,
motivation, social interaction, structural factors, and cultural
context are invited. Proposals for interdisciplinary and
community-collaborative research addressing HIV treatment adherence are
particularly encouraged.
The R03 grant mechanism supports different types of projects including
- pilot and feasibility studies;
- secondary analysis of existing data;
- small, self-contained research projects;
- development of research methodology; and
-
development of new research technology. The R03 is intended to support
small research projects that can be carried out in a short period of
time with limited resources. |
| Contact Address: |
Interested applicants should contact the relevant institute listed in "Section VII. Agency Contacts" of this announcement. |
| Contact Country: |
United States |
| URL for more information: |
http://grants1.nih.gov/grants/guide/pa-files/PA-07-339.html |
| Date Last Revised: |
March 5, 2008 |
| URL from COS to Bookmark this record: |
http://fundingopps.cos.com/cgi-bin/getRec?id=107012 |
| Keywords: |
AIDS Therapy
HIV
Medical Treatment
|
| Sponsor Reference No: |
PA-07-339 |
| Funding Type: |
Research
|
| COS Unique Id: |
107013 |
| Title: |
HIV Treatment Adherence Research (R21) |
| Sponsor: |
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
|
| Sponsor Type: |
Federal, U.S. |
| Deadline: |
June 16, 2008
October 16, 2008
February 16, 2009
|
| Deadline Note: |
This program announcement expires on January 8, 2010. |
| Upper Amount: |
$275,000 |
| Amount Note: |
This program will use the R21 grant mechanism. The
total project period for an application submitted in response to this
funding opportunity may not exceed two years. Although the size of
award may vary with the scope of research proposed, it is expected that
applications will stay within the budgetary guidelines for an
exploratory/developmental project; direct costs are limited to $275,000
over an R21 two-year period. |
| Eligibility: |
Applications may be submitted by domestic or
foreign, for-profit or nonprofit, public or private institutions, such
as universities, colleges, hospitals, and laboratories; units of state
and local government; and regional organizations. |
| Citizenship or Residency: |
Unrestricted
|
| Activity Location: |
Unrestricted
|
| Requirements: |
Small Business
Ph.D./M.D./Other Professional
Commercial
Government
Nonprofit
Academic Institution
|
| Abstract: |
This funding opportunity announcement (FOA), issued
by the National Institute of Mental Health (NIMH), National Institute
on Drug Abuse (NIDA), and National Institute of Nursing Research
(NINR), calls for research to advance the scientific understanding of
HIV treatment adherence and to enhance and expand available
intervention strategies to promote, improve, and sustain adherence. The
overarching emphasis is on the development of innovative behavioral and
structural adherence interventions that could be rapidly translated
into clinical practice, community venues, and public health policy
within domestic and international settings. Any descriptive studies
should therefore be undertaken with the aim of informing the mechanisms
of adherence interventions. Interventions may target patient adherence
to antiretroviral medications or other aspects of HIV treatment that
can be shown to affect patient outcomes and public health (e.g.,
linkage to primary care, medical appointment attendance, and service
utilization). Investigators are encouraged to consider incorporation of
clinical outcomes (e.g., viral load, CD4 T-cell count, drug resistance)
into intervention trials when feasible and scientifically appropriate.
Studies are also needed that will advance knowledge of effective
approaches for promoting the dissemination, adoption, and sound
implementation of tested adherence interventions. A well-articulated
and empirically based conceptual framework is essential for all
applications solicited under this announcement. Approaches based on
basic behavioral and social scientific principles such as cognition,
emotion, decision-making, motivation, social interaction, structural
factors, and cultural context are invited. Proposals for
interdisciplinary and community-collaborative research addressing HIV
treatment adherence are particularly encouraged.
The R21 grant
mechanism is intended to encourage exploratory and developmental
research projects by providing support for the early and conceptual
stages of these projects. These studies may involve considerable risk
but may lead to a breakthrough in a particular area, or to the
development of novel techniques, agents, methodologies, models, or
applications that could have a major impact on a field of biomedical,
behavioral, or clinical research. |
| Contact Address: |
Interested applicants should contact the relevant institute listed in "Section VII. Agency Contacts" of this announcement. |
| Contact Country: |
United States |
| URL for more information: |
http://grants1.nih.gov/grants/guide/pa-files/PA-07-340.html |
| Date Last Revised: |
March 5, 2008 |
| URL from COS to Bookmark this record: |
http://fundingopps.cos.com/cgi-bin/getRec?id=107013 |
| Keywords: |
AIDS Therapy
HIV
Medical Treatment
|
| Sponsor Reference No: |
PA-07-340 |
| Funding Type: |
Research
|
| COS Unique Id: |
107042 |
| Title: |
Mechanism for Time-Sensitive Research Opportunities (R21) |
| Sponsor: |
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
|
| Sponsor Type: |
Federal, U.S. |
| Deadline: |
March 19, 2008
April 21, 2008
May 20, 2008
June 20, 2008
|
| Deadline Note: |
Letter of intent receipt dates are four weeks prior to the planned submission date.
Application
submission dates in 2008 are March 19, 2008; April 21, 2008; May 20,
2008; June 20, 2008; July 21, 2008; August 20, 2008; September 19,
2008; October 20, 2008; November 20, 2008; and December 19, 2008.
Application
submission dates in 2009 are January 20, 2009; February 20, 2009; March
20, 2009; April 20, 2009; May 20, 2009; June 19, 2009; July 20, 2009;
August 20, 2009; September 21, 2009; October 20, 2009; November 20,
2009; December 21, 2009.
Application submission dates in 2010
are January 20, 2010; February 19, 2010; March 19, 2010; April 20,
2010; May 20, 2010; June 21, 2010; July 20, 2010.
This program will expire on July 21, 2010. |
| Upper Amount: |
$275,000 |
| Amount Note: |
This Funding Opportunity Announcement (FOA) invites
applications for exploratory/developmental research projects (R21) that
can be carried out in a short period of time with limited resources.
The total project period for an application submitted in response to
this funding opportunity may not exceed two years. Although the size of
award may vary with the scope of research proposed, it is expected that
applications will stay within the budgetary guidelines for an
exploratory/developmental project; direct costs are limited to $275,000
over an R21 two-year period, with no more than $200,000 in direct costs
allowed in any single year. Applicants may request direct costs in
$25,000 modules, up to the total direct costs limitation of $275,000
for the combined two-year award period. |
| Eligibility: |
Applications may be submitted by domestic and
foreign for-profit or nonprofit organizations and public or private
institutions, such as universities, colleges, hospitals, and
laboratories; units of state and local governments; eligible agencies
of the federal government; faith-based or community-based
organizations; and Native American tribal organizations. |
| Citizenship or Residency: |
Unrestricted
|
| Activity Location: |
Unrestricted
|
| Requirements: |
Small Business
Ph.D./M.D./Other Professional
Commercial
Government
Nonprofit
Academic Institution
|
| Abstract: |
The National Institute on Drug Abuse (NIDA) and the
National Institute of Environmental Health Sciences (NIEHS) have
released a funding opportunity announcement intended to support
substance abuse services research or hazard exposure-related research
in rapidly evolving areas (e.g., immediate aftermath of a disaster,
changes in service systems, health care financing, policy, industrial
accidents potentially affecting large populations or resources such as
a local water supply, major changes in land use or expansion of
facilities, such as a port or hazardous waste facility, located near
residential communities, etc.) where opportunities for empirical study
are, by their very nature, only available through expedited award of
support.
There are three distinguishing features of an eligible study:
1. The study's scientific value and feasibility are clear.
2.
Rapid review and funding are required in order for the scientific
question to be answered and for the research design to be carried out.
3. The knowledge gained from the study cannot be obtained through the
regular National Institutes of Health (NIH) cycle of review and award.
It should be clear that the research question offers an uncommon and
scientifically significant services research opportunity that could
only become available if the project is initiated with minimum delay.
In
particular, this program encourages innovative scientific partnerships
between researchers and community or public partners (e.g., public
substance abuse, mental health, or health care systems, long-term care
providers, criminal justice settings, health care providers, payers,
health authorities, etc.) who cannot delay policy or program changes in
order to obtain baseline research data related to such changes.
Research collaborations intended to answer unique and innovative
questions concerning changes in a health care system or policy are of
most interest.
Examples of appropriate studies include, but are not limited to, the following:
1. Examining the impact of rapid changes in policy or legislation that affect delivery of substance abuse services and treatment
2.
Evaluating the impact of systems interventions or quality improvement
of new evidence-based practice programs implemented as an immediate
response to administrative or policy directives
3. Determining the
cost-effectiveness for rapidly changing or emerging treatment
alternatives, services, or structures for provision of services
4.
Prospectively identifying, describing, or tracking individual, family,
provider, organizational, or systems-level outcomes resulting from
rapidly changing services or benefits
5. Determining the impact of a disaster on the organization or delivery of services and treatment systems
6.
Sampling of air, water, and soil as well as health parameters of
individuals following a natural disaster or in anticipation of the
expansion of a major facility, such as a port, in proximity to
residential areas in order to establish a baseline for subsequent
comparison and determination of the health effects due to the release
of air, water, or soil contaminants
7. Examining the impact of rapid
changes in policy or legislation that affect exposure of local
populations to hazardous waste or increased air pollution through
changing traffic patterns
8. Needs assessment of local health
officials in the face of natural disasters with the goal of improving
training tools and communications among first-responders
Within
the areas of drug abuse research, appropriate studies encompass
services research related to drug use, misuse, and disorders. In
addition, investigators are encouraged to examine the impact of the
time-sensitive event on the intersection of substance use and substance
use disorders with HIV/AIDS risk factors and services.
The R21
mechanism is intended to encourage new exploratory and developmental
research projects. For example, such projects could assess the
feasibility of a novel area of investigation or a new experimental
system that has the potential to enhance health-related research.
Another example could include the unique and innovative use of an
existing methodology to explore a new scientific area. These studies
may involve considerable risk but may lead to a breakthrough in a
particular area, or to the development of novel techniques, agents,
methodologies, models, or applications that could have a major impact
on a field of biomedical, behavioral, or clinical research.
Additional Contact:
Ms. Carolyn Mason, Deputy Grants Management Officer
Grants Management Branch
National Institute of Environmental Health Sciences
P.O. Box 12233
79 T.W. Alexander Drive, MD EC-22
Research Triangle Park, North Carolina 27709
Phone +1 (919) 541-1373
Fax +1 (919) 541-2860
mason6@niehs.nih.gov |
| Contact Name: |
Edith Davis |
| Contact Address: |
Grants Management Branch
National Institute on Drug Abuse/NIH/DHHS
6101 Executive Boulevard, Room 270 |
| Contact City: |
Bethesda |
| Contact State: |
Maryland |
| Contact Zip: |
20892 |
| Contact Country: |
United States |
| Contact Phone: |
+1 (301) 443-6710 |
| Contact Email: |
edavis1@nida.nih.gov |
| URL for more information: |
http://grants1.nih.gov/grants/guide/pa-files/PAR-07-345.html |
| Date Last Revised: |
March 5, 2008 |
| URL from COS to Bookmark this record: |
http://fundingopps.cos.com/cgi-bin/getRec?id=107042 |
| Keywords: |
Environmental Health
Environmental Medicine
Substance Abuse
|
| Sponsor Reference No: |
PAR-07-345 |
| Funding Type: |
Research
|
| COS Unique Id: |
107634 |
| Title: |
Grants for Basic Research in Glomerular Diseases (R01) |
| Sponsor: |
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Sponsor Type: |
Federal, U.S. |
| Deadline: |
June 5, 2008
October 5, 2008
February 5, 2009
|
| Deadline Note: |
This program will expire on March 6, 2010. |
| Amount Note: |
This program will use the R01 grant mechanism.
Because the nature and scope of the proposed research will vary from
application to application, it is anticipated that the size and
duration of each award will also vary. |
| Eligibility: |
Applications may be submitted by domestic or
foreign, for-profit or nonprofit organizations and public or private
institutions, such as universities, colleges, hospitals, and
laboratories; units of state and local governments; eligible agencies
of the federal government; and faith-based or community-based
organizations. |
| Citizenship or Residency: |
Unrestricted
|
| Activity Location: |
Unrestricted
|
| Requirements: |
Small Business
Ph.D./M.D./Other Professional
Commercial
Government
Nonprofit
Academic Institution
|
| Abstract: |
The Division of Kidney, Urologic, and Hematologic
Diseases (DKUHD) of the National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK) invites applications from new or
established investigators to pursue basic exploratory investigations of
glomerular disease, which would foster development of new ideas
enhancing the understanding of disease detection, pathogenesis,
pre-emption, and treatment.
Recent observations regarding
intrinsic glomerular cell biology, particularly in the podocyte, have
provided exciting new insights into potential pathogenic mechanisms of
human glomerular disease. Although both immune and nonimmune mechanisms
of glomerular injury have been studied previously, experimental models
of disease and recent techniques that provide tools for molecular and
proteomic profiling show great promise for identifying glomerular
disease biomarkers. Despite these recent advances, additional basic
studies are needed to facilitate a better understanding of glomerular
disease pathogenesis and ultimately impact on the treatment of human
glomerulopathies.
It is anticipated that applications
submitted in response to this FOA could address a number of different
aspects concerning the pathogenesis, natural history, therapy
pre-emption, or prevention of the various morphologic forms of
experimental glomerular disease.
Relevant topics of study for basic research evaluating glomerular disease could include, but are not limited to,
- understanding basic glomerular cell biology;
-
understanding pathogenic mechanisms of specific forms of glomerular
disease, such as IgA nephropathy, primary focal and segmental
glomerulosclerosis, idiopathic membranous nephropathy, lupus nephritis,
membranoproliferative glomerulonephritis, and small vessel renal
vasculitis;
- development of new animal models for specific forms of glomerular disease;
- development of new glomerular-specific imaging techniques; and
- identification and characterization of glomerular disease biomarkers. |
| Contact Name: |
Carolyn Kofa, Grants Management Specialist |
| Contact Address: |
National Institute of Diabetes and Digestive and Kidney Diseases
6707 Democracy Boulevard, Room 727 |
| Contact City: |
Bethesda |
| Contact State: |
Maryland |
| Contact Zip: |
20892-5456 |
| Contact Country: |
United States |
| Contact Phone: |
+1 (301) 594-7687 |
| Contact Fax: |
+1 (301) 480-3504 |
| Contact Email: |
ck104i@nih.gov |
| URL for more information: |
http://grants1.nih.gov/grants/guide/pa-files/PA-07-367.html |
| Date Last Revised: |
March 7, 2008 |
| URL from COS to Bookmark this record: |
http://fundingopps.cos.com/cgi-bin/getRec?id=107634 |
| Keywords: |
Kidney Disease
Pathogenesis
|
| Sponsor Reference No: |
PA-07-367 |
| Funding Type: |
Research
|
| COS Unique Id: |
107744 |
| Title: |
Simian Models for the Oral Biology of HIV Infection and AIDS-Related Oral Complications (R21) |
| Sponsor: |
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Dental and Craniofacial Research (NIDCR)
|
| Sponsor Type: |
Federal, U.S. |
| Deadline: |
June 16, 2008
October 16, 2008
February 16, 2009
|
| Deadline Note: |
This program will expire on May 8, 2010. |
| Upper Amount: |
$275,000 |
| Amount Note: |
This funding opportunity will use the R21
Exploratory/Development Grant award mechanism. The total project period
for an application submitted in response to this funding opportunity
may not exceed two years. Direct costs are limited to $275,000 over the
two years of the R21 award, with no more than $200,000 in direct costs
allowed in any single year. Applicants may request direct costs in
$25,000 modules, up to the total direct costs limitation of $275,000
for the combined two-year award period. |
| Eligibility: |
Applications may be submitted by domestic or
foreign, for-profit or nonprofit organizations and public or private
institutions, such as universities, colleges, hospitals, and
laboratories; units of state and local governments; and regional
organizations. |
| Citizenship or Residency: |
Unrestricted
|
| Activity Location: |
Unrestricted
|
| Requirements: |
Small Business
Ph.D./M.D./Other Professional
Commercial
Government
Nonprofit
Academic Institution
|
| Abstract: |
This funding opportunity announcement (FOA) issued
by the National Institute of Dental and Craniofacial Research (NIDCR)
solicits applications that will use nonhuman primate models to study
the oral biology of HIV infection and the oral complications associated
with AIDS. This is an exploratory/developmental award with limited
funding that is designed to maximize the use of animals currently
involved in ongoing studies. Studies that will increase knowledge of
the basic biology, pathogenic mechanisms, immunology, diagnosis,
treatment, and prevention of oral HIV/AIDS in simian macaque models are
requested. Exploratory projects in emerging areas of importance for
oral manifestations of AIDS and other acquired immunodeficiencies are
of particular interest. It is expected that investigators will base
their studies on recent developments in the field and will make use of
the new and emerging state of the art technologies.
Examples of research responsive to this FOA are listed below but are by no means inclusive:
1.
Investigate and compare innate and adaptive immune networks of oral,
vaginal, and rectal mucosal epithelial surfaces as they relate to
Simian Immunodeficiency Virus (SIV)/Simian Human Immunodeficiency Virus
(SHIV) infection.
2. Studies that will increase understanding of the
mechanisms involved in maintaining the balance between inductive
vaccine responses and tolerance to facilitate the development of oral
mucosal vaccines against HIV
3. Determine the structural,
biological, and functional properties of oropharyngeal mucosa that
makes it relatively resistant to HIV but susceptible to other viral
pathogens.
4. Identify and compare salivary components from infant
or adult macaques that interact with SHIV and possibly control
susceptibility of oral epithelium to SIV infection.
5. Determine the
impact of co-infections, inflammatory diseases, and tissue injury on
mucosal susceptibility to SIV and development of AIDS.
6.
Characterization of oral mucosal changes associated with immune
reconstitution inflammatory syndrome (IRIS) in human primate models for
AIDS
7. Compare the structural, biological, and functional
properties of oral mucosa from infants and adults to define the
developmental impact on the susceptibility to HIV infection.
8.
Determine the early events occurring in the oral mucosa and
oropharyngeal lymphoid tissues following acute infection with SHIV and
investigate whether the oral mucosa permits entry, transcytosis,
harboring, and shedding of SHIV.
9. Determine the immunological,
virological, and biochemical basis of lesions induced by chronic viral
infections of the oral cavity (e.g., papilloma virus, Kaposi sarcoma
herpes virus, cytomegalovirus, etc.) in the context of SIV/SHIV
infection. |
| Contact Name: |
Mary Daley |
| Contact Address: |
Grants Management Branch
National Institute of Dental and Craniofacial Research
Building 45, Room 4AN44B
45 Center Drive, MSC 6402 |
| Contact City: |
Bethesda |
| Contact State: |
Maryland |
| Contact Zip: |
20892-6402 |
| Contact Country: |
United States |
| Contact Phone: |
+1 (301) 594-4808 |
| Contact Fax: |
+1 (301) 480-3562 |
| Contact Email: |
md74u@nih.gov |
| URL for more information: |
http://grants1.nih.gov/grants/guide/pa-files/PA-07-369.html |
| Date Last Revised: |
March 7, 2008 |
| URL from COS to Bookmark this record: |
http://fundingopps.cos.com/cgi-bin/getRec?id=107744 |
| Keywords: |
Animal Models
HIV
Infectious Diseases or Agents
Oral Diseases
|
| Sponsor Reference No: |
PA-07-369 |
| Funding Type: |
Research
|
| COS Unique Id: |
112896 |
| Title: |
Integrated Preclinical/Clinical Program for HIV Topical Microbicides (U19) |
| Sponsor: |
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
|
| Sponsor Type: |
Federal, U.S. |
| Deadline: |
July 17, 2008
|
| Deadline Note: |
An optional letter is due June 17, 2008. This opportunity will expire on July 18, 2008.
Internal
coordination required. A principal investigator (PI) may submit only
one application; however, a PI may serve as a project leader or
scientific core leader in multiple applications, provided there is no
scientific overlap with the application submitted by the PI. |
| Amount Note: |
This RFA will use the multi-project Cooperative
Agreement (U19) award mechanism. Two to three new awards are
anticipated in response to this RFA. An applicant may request a project
period of up to four years for applications without pre-Phase 1
clinical trials, and up to five years for applications with pre-Phase 1
clinical trials.
Budget requests may not exceed the stated
upper limits for each of the categories listed. The total annual direct
costs for current IPCP-HTM awards with the following activities range
from
- $0.5 million to $0.9 million for basic and preclinical research;
-
$0.9 million to $1.2 million for basic and preclinical research that
involves non-human primate studies designed to assess the efficacy or
safety of a microbicide candidate or strategy; and - $1.2 million to
$1.6 million for awards involving exploratory pre-Phase 1 clinical
trials.
This program does not require cost sharing. |
| Eligibility: |
Eligible organizations include for-profit and
nonprofit organizations; public or private institutions, such as
universities, colleges, hospitals, and laboratories; units of state and
local government; eligible agencies of the federal government; and
faith-based or community-based organizations. |
| Citizenship or Residency: |
Unrestricted
|
| Activity Location: |
Unrestricted
|
| Requirements: |
Small Business
Ph.D./M.D./Other Professional
Commercial
Government
Nonprofit
Academic Institution
|
| Abstract: |
The National Institute of Allergy and Infectious
Diseases (NIAID) and the National Institute of Mental Health (NIMH)
invite applications from single institutions and consortia of
institutions to participate in the Integrated Preclinical/Clinical
Program for HIV Topical Microbicides (IPCP-HTM) for the advancement of
novel single and combination safe, effective, and acceptable
microbicides and microbicide strategies to prevent sexual transmission
of HIV. The types of microbicide research that will be supported by the
IPCP-HTM include basic microbicide science, focused preclinical
development, and exploratory small scale clinical trials - hereinafter
referred to as pre-Phase I clinical trials. The IPCP-HTM is
specifically designed to serve as a platform for microbicide
development through support for integrated and iterative research
projects and activities including, but not limited to,
- microbicide-relevant basic science;
- drug discovery-driven development of microbicides;
- preclinical virologic and toxicologic assessment of lead candidates;
- development and validation of Good Laboratory Practice (GLP)-compliant analytical assays; and
-
Good Manufacturing Practice (GMP)-manufacturing activities in support
of pre-Phase I clinical trials. Applications may include any
combination of these activities. Proposed programs are not required to
include all activities that might constitute the complete development
path from discovery to pre-Phase I clinical trials.
While
pre-Phase I clinical trials may be supported under the IPCP-HTM, this
funding opportunity announcement (FOA) will not support Phase I, II, or
III clinical trials. |
| Contact Name: |
Quadira Huff |
| Contact Address: |
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
Room 2231, MSC-7614, 6700 B Rockledge Drive |
| Contact City: |
Bethesda |
| Contact State: |
Maryland |
| Contact Zip: |
20892-7614 |
| Contact Country: |
United States |
| Contact Phone: |
+1 (301) 451-2696 |
| Contact Fax: |
+1 (301) 493-0591 |
| Contact Email: |
huffq@niaid.nih.gov |
| URL for more information: |
http://grants1.nih.gov/grants/guide/rfa-files/RFA-AI-08-006.html |
| Date Last Revised: |
March 4, 2008 |
| URL from COS to Bookmark this record: |
http://fundingopps.cos.com/cgi-bin/getRec?id=112896 |
| Keywords: |
Antimicrobial Agents
HIV
|
| Sponsor Reference No: |
RFA-AI-08-006 |
| Funding Type: |
Collaboration or Cooperative Agreement
Research
|
| COS Unique Id: |
112943 |
| Title: |
Partnerships for Point of Care (POC) Diagnostic Technologies for Nontraditional Health Care Settings (U01) |
| Sponsor: |
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
|
| Sponsor Type: |
Federal, U.S. |
| Deadline: |
June 30, 2008
|
| Deadline Note: |
A non-required letter of intent is due May 30, 2008. This opportunity will expire on July 1, 2008. |
| Upper Amount: |
$2,500,000 |
| Amount Note: |
This FOA will utilize the single-project
Cooperative Agreement (U01) grant mechanism. NIAID anticipates awarding
a total of $4 million in FY 2009 to fund four to six awards. Annual
direct costs are limited to $500,000 per award. The total project
period for an application submitted in response to this FOA may not
exceed five years.
This program does not require cost sharing. |
| Eligibility: |
Applications may be submitted by domestic or
foreign, for-profit or nonprofit organizations and public or private
institutions, such as universities, colleges, hospitals, and
laboratories; units of state and local governments; eligible agencies
of the federal government; and faith-based or community-based
organizations. Institutions must be in compliance with U.S. laws and
regulations and DHHS and NIH policies in effect at the time of grant
award and during the period of performance of the research.
The
project director or principal investigator (PD or PI) of the
application may be affiliated with industry, an academic organization,
or a nonprofit research organization (if academia or the nonprofit is
part of a partnership with industry). |
| Citizenship or Residency: |
Unrestricted
|
| Activity Location: |
Unrestricted
|
| Requirements: |
Small Business
Ph.D./M.D./Other Professional
Commercial
Government
Nonprofit
Academic Institution
|
| Abstract: |
Through this RFA, the the National Institute of
Allergy and Infectious Diseases (NIAID) invites research applications
for product development activities that will lead to new or improved
partnerships for point of care (POC) diagnostic technologies for
infectious disease-causing pathogens or toxins in nontraditional health
care settings. Product development for POC diagnostic technologies
should encompass development of new or improved methods, tools, or
devices for sample collection, processing, and detection with broad
applicability to a variety of body sites and specimens (for example the
nasopharynx, genital tract, urinary tract, and whole blood), and that
are operational in nontraditional health care settings. Nontraditional
health care settings include the home, rural and urban community public
health care clinics, and temporary health care clinics established in
response to a natural or man-made disaster. Examples of research may
include improved self-collection methodology, single unit swab and
fluid processing, non-sterile collection devices with preservation
capability, and integrated collection and processing methods for use in
home-based test kits or for public health-based POC diagnostic testing.
The
goal of the NIAID partnerships programs is to stimulate industry
participation in the development of vaccines, drugs, and diagnostics
for human infectious diseases of public health importance. A key
component of this initiative is the development of partnerships between
academia and industry. For the purpose of this RFA, "industry" is
defined as large and small, domestic or foreign, pharmaceutical,
biotechnology, bioengineering, and chemical companies. Since academic
organizations are often the source of new technologies and candidate
products, this RFA will support partnerships between industry and
collaborator(s) from academic and nonprofit research organizations. The
involvement of an academic or nonprofit research organization is not a
requirement; therefore, industry does not need a collaborator to submit
an application to this program.
Industry participation is
mandatory. All applications must demonstrate substantive involvement by
the industry partner. For the purpose of this RFA, "substantive
involvement" is defined as the commitment of any one or more of the
following resources:
1. Funds
2. Personnel
3. In-kind
contributions of materials or reagents including, but not limited to,
recombinant protein production, provision of animals or assays, data
management resources, or regulatory support
Applications that do
not demonstrate substantive industry participation will be considered
non-responsive and will not be reviewed. It is anticipated that this
program will stimulate multidisciplinary approaches to develop or
improve POC diagnostic technologies for use in nontraditional health
care settings, which could include microbiology, clinical infectious
diseases, bioengineering, and platform technologies.
Basic
research to support the initial development of POC diagnostic
technologies will not be supported. The application must propose the
development of a previously identified candidate POC diagnostic
technology and include proof-of-concept data demonstrating the
feasibility of the technology.
While clinical development
strategies may be included within an overall product development plan,
and the utilization of archived or prospectively collected human
samples in the early phases of development as well as in the evaluation
of proposed tools in preclinical studies is considered responsive and
is encouraged, this RFA will not support Phase I, II, and III clinical
trials or field trials. Applications requesting support for clinical
trials will be viewed as unresponsive to this RFA and will not be
reviewed.
This RFA will not support research on detection technologies for NIAID Category A, B, and C priority pathogens.
Research
supported and conducted by NIAID strives to understand, diagnose,
treat, and ultimately prevent the myriad infectious, immunologic, and
allergic diseases that threaten millions of human lives. NIAID supports
extramural research to control and prevent diseases caused by virtually
all infectious agents. This includes
- basic biomedical research, such as studies of microbial physiology and antigenic structure;
- immunity;
- applied research, including the development of diagnostic tests; and
- clinical trials to evaluate experimental drugs and vaccines. |
| Contact Name: |
Kathryn Ellis |
| Contact Address: |
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
Room 2240, MSC-7614, 6700-B Rockledge Drive |
| Contact City: |
Bethesda |
| Contact State: |
Maryland |
| Contact Zip: |
20892 |
| Contact Country: |
United States |
| Contact Phone: |
+1 (301) 451-2687 |
| Contact Fax: |
+1 (301) 493-0597 |
| Contact Email: |
kellis@niaid.nih.gov |
| URL for more information: |
http://grants1.nih.gov/grants/guide/rfa-files/RFA-AI-08-003.html |
| Date Last Revised: |
March 7, 2008 |
| URL from COS to Bookmark this record: |
http://fundingopps.cos.com/cgi-bin/getRec?id=112943 |
| Keywords: |
Biomedical Engineering
Infectious Diseases or Agents
Medical Diagnosis
Medical Technology
|
| Sponsor Reference No: |
RFA-AI-08-003 |
| Funding Type: |
Collaboration or Cooperative Agreement
Research
|
| COS Unique Id: |
112944 |
| Title: |
Development of Novel Interventions and Tools for the Control of Malaria, Neglected Tropical Diseases, and Their Vectors (R01) |
| Sponsor: |
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
|
| Sponsor Type: |
Federal, U.S. |
| Deadline: |
July 10, 2008
|
| Deadline Note: |
A non-required letter of intent is due June 10, 2008. This opportunity will expire on July 11, 2008.
Resubmission
applications are not permitted in response to this FOA. Renewal
applications are not permitted in response to this FOA. |
| Amount Note: |
This FOA will utilize the NIH Research Project
Grant (R01) grant mechanism. The NIH has committed $4 million in total
costs in FY2009 to support this program and anticipates that four to
six awards will be made. Awards issued under this FOA are contingent
upon the availability of funds, the submission of a sufficient number
of meritorious applications, and relevance of program priorities. The
total project period for an application submitted in response to this
FOA may not exceed five years.
This program does not require cost sharing. |
| Eligibility: |
Applications may be submitted by domestic or
foreign, for-profit or nonprofit organizations and public or private
institutions, such as universities, colleges, hospitals, and
laboratories; units of state and local governments; eligible agencies
of the federal government; and faith-based or community-based
organizations. |
| Citizenship or Residency: |
Unrestricted
|
| Activity Location: |
Unrestricted
|
| Requirements: |
Small Business
Ph.D./M.D./Other Professional
Commercial
Government
Nonprofit
Academic Institution
|
| Abstract: |
The purpose of this funding opportunity
announcement (FOA) issued by the National Institute of Allergy and
Infectious Diseases (NIAID) is to support and stimulate translational
research leading to the development of novel and more effective
interventions and research tools (e.g., genetic and computational
tools) that will facilitate and promote the discovery and development
of novel therapeutics, vaccines, diagnostics, and vector management
strategies, thereby reducing or eliminating morbidity and mortality
from malaria and Neglected Tropical Diseases (NTDs). Projects that
propose to develop molecular tools and biomarkers to support the
development of novel and more effective interventions are also included
in this initiative.
For the purposes of this FOA, the diseases
considered to be Neglected Tropical Diseases are limited to the
following infectious agents and the corresponding vectors responsible
for their transmission:
1. African trypanosomiasis (sleeping sickness)
2. American trypanosomiasis (Chagas' disease)
3. Buruli ulcer
4. Intestinal helminth (roundworm) infections
5. Leishmaniasis
6. Leprosy
7. Lymphatic/Bancroftian filariasis (elephantiasis)
8. Onchocerciasis (river blindness)
9. Schistosomiasis
10. Trachoma
Applications
that do not have a focus on these diseases or the corresponding vectors
will be considered non-responsive to this FOA as determined by the
NIAID program staff and will not be reviewed. Applications that do not
have a focus on translational research will be considered
non-responsive to this FOA as determined by the NIAID program staff and
will not be reviewed. Applications focused on genital infection by C.
trachomatis or that utilize genital models of C. trachomatis infection
will also be considered non-responsive to this FOA and will not be
reviewed.
For diseases covered by this FOA, translational
research is defined as the stage of research at which a potential
target, molecule, metabolic pathway, gene product, etc. is ready for
validation or proof of concept as a prospective tool/intervention for
diagnosis, prevention, or treatment of these diseases. Examples of the
types of research on pathogens causing malaria and NTDs that could be
supported under this program include, but are not limited to, the
following:
1. Development of molecular, genetic, and computational
tools for genome-wide identification and analysis of potential targets
for the development of therapeutics, vaccines, and diagnostics
2. Evaluation of the mechanism of action and mechanisms of resistance of currently used drugs and novel lead compounds
3. Development of animal models for disease and correlates of drug and vaccine efficacy
4. Evaluation of the efficacy of candidate interventions in animal models
5. Preclinical evaluation of the safety, toxicology, or immunogenicity of candidate interventions
6.
Preclinical studies required to support submission and review of an
Investigational New Drug (IND) or Investigational Device Exemption (IDE)
7.
Development of candidate biomarkers of disease genetic diversity,
virulence, and drug resistance to support the development of
interventions
8. Research to support the development and evaluation of Point-of-Care diagnostics and tools for screening
For
vectors, translational research is defined as the stage of research at
which a potential target, molecule, metabolic pathway, gene product,
etc. is ready for validation or proof of concept as a prospective
tool/intervention for vector management. Examples include, but are not
limited to, the following:
1. Development of molecular, genetic, and
computational tools for genome-wide analysis of potential targets for
the development of insecticides and repellents
2. Development of
tools for monitoring vector species or pathogen presence in the vector
that will contribute to more effective disease monitoring under field
conditions
3. Development of a system to evaluate the
epidemiological impact of a vector management strategy or identify
entomological correlates of disease prevention that can be monitored
4. Identification of biomarkers to monitor the prevalence and development of insecticide resistance
5. Strategies that will prevent transmission of pathogens from vector to humans
6. Development of tools to accurately identify vector species, especially in cases where species complexes exist
7.
Development of genomic tools that can be applied to field-based
technologies for monitoring vector populations (i.e., susceptibility or
resistance to insecticides, bloodmeal analysis, infection with
pathogen, etc.)
While strategies for clinical development, which
may be part of an investigator's overall product development plan, may
be included in the application to provide supporting information and
context, this FOA will not support clinical trials or field trials.
Applications requesting support for clinical or field trials will not
be reviewed. Field assessments of interventions not involving human
subjects are permitted under this FOA, and utilization of human cell
lines and human derived samples to support preclinical development
complying with regulatory requirements is encouraged. |
| Contact Name: |
Kimberly Chatman |
| Contact Address: |
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
Room 2241, MSC-7616, 6700B Rockledge Drive |
| Contact City: |
Bethesda |
| Contact State: |
Maryland |
| Contact Zip: |
20892-7616 |
| Contact Country: |
United States |
| Contact Phone: |
+1 (301) 402-6580 |
| Contact Fax: |
+1 (301) 493-0597 |
| Contact Email: |
chatmank@niaid.nih.gov |
| URL for more information: |
http://grants1.nih.gov/grants/guide/rfa-files/RFA-AI-08-005.html |
| Date Last Revised: |
March 7, 2008 |
| URL from COS to Bookmark this record: |
http://fundingopps.cos.com/cgi-bin/getRec?id=112944 |
| Keywords: |
Infectious Diseases or Agents
Malaria
Tropical Medicine
|
| Sponsor Reference No: |
RFA-AI-08-005 |
| Funding Type: |
Research
|
| COS Unique Id: |
43076 |
| Title: |
AAPS New Investigator Grant in Pharmaceutics and the Pharmaceutical Technologies |
| Sponsor: |
American Association of Pharmaceutical Scientists (AAPS)
|
| Sponsor Type: |
Private Foundation |
| Deadline: |
May 9, 2008
|
| Amount: |
$25,000 |
| Upper Amount: |
$26,500 |
| Amount Note: |
The award consists of $25,000, a certificate that
will be presented to the award recipient at the 2008 AAPS Annual
Meeting and Exposition, and reimbursed travel expenses (up to $1,000
domestic or $1,500 international). All funds must be provided to the
researcher; none of the money may be used for university overhead,
indirect, or administrative costs. |
| Eligibility: |
Nominees must demonstrate a commitment to conduct
research in basic pharmaceutics, dosage form design, or the
pharmaceutical technologies, and have the potential for outstanding
achievement in teaching and research in these areas, as well as the
potential to be future leaders in pharmaceutical education and
research. Nominees must have less than four years of academic
experience and less than seven years of total postdoctoral experience.
A letter of nomination is required from the nominee's dean, department
chair, or division director. |
| Citizenship or Residency: |
Unrestricted
|
| Activity Location: |
Unrestricted
|
| Requirements: |
Ph.D./M.D./Other Professional
|
| Abstract: |
The Pharmaceutics and Drug Delivery and
Pharmaceutical Technologies Sections of the American Association of
Pharmaceutical Sciences (AAPS) annually sponsor a grant to support new
academic researchers during the early stages of their careers. The
award is a one-time grant to be used to support the research effort of
an individual actively engaged in training graduate students and
carrying out basic research in pharmaceutics, drug delivery, or the
pharmaceutical technologies, or any combination thereof. |
| Contact Address: |
American Association of Pharmaceutical Sciences
2107 Wilson Boulevard, Suite 700 |
| Contact City: |
Arlington |
| Contact State: |
Virginia |
| Contact Zip: |
22201-3046 |
| Contact Country: |
United States |
| Contact Phone: |
+1 (703) 243-2800 |
| Contact Fax: |
+1 (703) 243-9650 |
| Contact Email: |
awards@aaps.org |
| URL for more information: |
http://www.aapspharmaceutica.com/inside/awards_fellows/AwardDescriptions.asp |
| Date Last Revised: |
March 3, 2008 |
| URL from COS to Bookmark this record: |
http://fundingopps.cos.com/cgi-bin/getRec?id=43076 |
| Keywords: |
Dosage Forms
Drug Delivery Systems
Methods of Drug Delivery
Pharmaceuticals
Pharmacology
Pharmacy
|
| Funding Type: |
Research
|
| COS Unique Id: |
69330 |
| Title: |
Idea Development Awards |
| Sponsor: |
United States Department of Defense (DOD)
Department of the Army
U.S. Army Medical Research and Materiel Command (USAMRMC)
Congressionally Directed Medical Research Programs (CDMP)
Tuberous Sclerosis Complex Research Program (TSCRP)
|
| Sponsor Type: |
Federal, U.S. |
| Deadline: |
May 22, 2008
|
| Deadline Note: |
Pre-applications are due by May 22, 2008. The deadline for submission of proposals is June 12, 2008. |
| Upper Amount: |
$450,000 |
| Amount Note: |
Funding for an Idea Development Award can be
requested for up to $450,000 for direct costs for up to a three-year
performance period, plus indirect costs as appropriate. |
| Eligibility: |
Applicants must be independent investigators at the
assistant professor level (or equivalent) or above. Eligible
institutions include for-profit, nonprofit, public, and private
organizations. |
| Citizenship or Residency: |
Unrestricted
|
| Activity Location: |
Unrestricted
|
| Requirements: |
Ph.D./M.D./Other Professional
|
| Abstract: |
The Department of Defense (DOD) Tuberous Sclerosis
Complex Research Program (TSCRP) is funded to promote research directed
toward a better understanding of the role and function of proteins
produced by the TSC1 and TSC2 tumor suppressor genes, in accordance
with the directives received from Congress. Idea Development Awards are
intended to encourage innovative research directed toward improved
prevention, diagnosis, and/or treatment of tuberous sclerosis. |
| Contact Country: |
United States |
| Contact Phone: |
+1 (301) 619-7079 |
| Contact Fax: |
+1 (301) 619-7792 |
| Contact Email: |
cdmrp.pa@amedd.army.mil |
| URL for more information: |
http://cdmrp.army.mil/funding/tscrp.htm |
| Date Last Revised: |
March 6, 2008 |
| URL from COS to Bookmark this record: |
http://fundingopps.cos.com/cgi-bin/getRec?id=69330 |
| Keywords: |
Disease Control
Disease Prevention
Diseases and Disorders
Neurodegenerative Diseases
Radiology
|
| Sponsor Reference No: |
W81XWH-08-TSCRP-IDA |
| Funding Type: |
Research
|
| COS Unique Id: |
99241 |
| Title: |
Pilot Studies in Pancreatic Cancer (R03) |
| Sponsor: |
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Cancer Institute (NCI)
|
| Sponsor Type: |
Federal, U.S. |
| Deadline: |
June 16, 2008
|
| Deadline Note: |
This program announcement expires on September 8, 2008. |
| Upper Amount: |
$100,000 |
| Amount Note: |
This program will use the NIH R03 award mechanism.
A project period of up to two years and a budget for direct costs of up
to two $25,000 modules, or $50,000 per year, may be requested (i.e., a
maximum of $100,000 over two years in four modules of $25,000 each). |
| Eligibility: |
Applications may be submitted by domestic and
foreign, for-profit or non-profit organizations and public or private
institutions, such as universities, colleges, hospitals, and
laboratories; units of state and local governments; eligible agencies
of the federal government; and faith-based or community-based
organizations. |
| Citizenship or Residency: |
Unrestricted
|
| Activity Location: |
Unrestricted
|
| Requirements: |
Small Business
Ph.D./M.D./Other Professional
Commercial
Government
Nonprofit
Academic Institution
|
| Abstract: |
The purpose of this initiative funded by the
National Cancer Institute (NCI) is to promote innovative research
across multiple disciplines to better understand the etiology of
pancreatic cancer and to promote its early detection, prevention, and
treatment.
Specific topics of interest include, but are not limited to, the following:
1.
Identification of genetic aberrations or combinations of aberrations
and alterations that initiate or promote pancreatic cancer
2.
Development of experimental models for human pancreatic cancer to
facilitate the understanding of molecular carcinogenesis, to help
identify promising molecular targets, and to test new preventive and
therapeutic strategies
3. Exploration of molecular pathways using
human cell lines or tissues to identify novel targets for prevention or
therapeutic development
4. Examination of how variations in cells may combine with the microenvironment in the development of pancreatic cancer
5.
Evaluation of the roles of inflammation, tumor stem cells, energy
balance, and biological and chemical agents that contribute to cancer
6. Assessment of the roles of HBV, HCV, and Helicobacter pylori (H. pylori) infections in development of cancer
7. Identification of markers for early detection of cancer
8.
Conduct of preclinical studies to identify candidate chemopreventive
drugs and dietary factors for prevention and to characterize the
molecular mechanisms of the agent's activity
9. Conduct of
preclinical studies to identify and characterize candidate biomarkers
for pancreatic cancer risk, i.e., factors modifying pancreatic
etiologic events or exposures
10. Development of early-stage clinical trials in pancreatic cancer prevention and therapy
11.
Conduct of small exploratory clinical trials with a potential
chemopreventive agent assessing response via endoscopic ultrasound or
another similar technology
12. Conduct of proteomic profiling
studies to discriminate among sera of pancreatic cancer case patients,
chronic pancreatitis patients, and control subjects to provide initial
data on the performance characteristics (positive predictive value,
negative predictive value) of the method in detecting pancreatic
neoplasia or other diseases
13. Evaluation of serum expression
profiles from pancreatic cancer patients collected prospectively and
following surgical resection to determine the stability of the
diagnostic profiles and demonstrate the utility of this methodology in
providing an early marker of pancreatic cancer recurrence
14.
Assessment of any associations of tumor pathophysiology with tumor
development, progression, and preventive or therapeutic response
15. Conduct of ancillary imaging studies in pancreatic cancer clinical trials
16. Conduct of correlative studies using specimens from multi-institutional prevention and treatment trials to study outcomes
17.
Conduct of exploratory studies to identify and evaluate biomarkers to
determine prognosis and predict response to therapy in pancreatic
cancer
18. Evaluation of combination therapies for pancreatic cancer
19. Identification of "new" environmental exposures that contribute to pancreatic cancer including adverse energy balance
20. Development of a biofluid-based test for pancreatic cancer that can be used in population studies
21. Determination of what combination of "two hits" - genetic or environmental - are needed for pancreatic cancer to develop
22. Assessment of the impact of pancreatic cancer on health-related quality of life of patients and their caregivers
23. Conduct of pilot surveillance studies and generation of survivorship registries
24. Identification of factors that contribute to disparity in incidence of pancreatic cancer among populations |
| Contact Name: |
Mukesh Verma, Ph.D. |
| Contact Address: |
National Cancer Institute
Division of Cancer Control and Population Sciences
6130 Executive Boulevard, EPN Room 5104, MSC 7324 |
| Contact City: |
Bethesda |
| Contact State: |
Maryland |
| Contact Zip: |
20892-7324 |
| Contact Country: |
United States |
| Contact Phone: |
+1 (301) 594-7344 |
| Contact Fax: |
+1 (301) 402-4279 |
| Contact Email: |
vermam@mail.nih.gov |
| URL for more information: |
http://grants1.nih.gov/grants/guide/pa-files/PA-06-314.html |
| Date Last Revised: |
March 3, 2008 |
| URL from COS to Bookmark this record: |
http://fundingopps.cos.com/cgi-bin/getRec?id=99241 |
| Keywords: |
Antineoplastic Agents
Biomarkers
Biomedical Research (Multidisciplinary)
Cancer Biology
Cancer or Carcinogenesis
Cancer Prevention
Caregiving
Chemical Carcinogenesis
Chemotherapeutic Agents
Chemotherapy
Clinical Trial
Disease Model
Endoscopy
Etiology
Genetic Diseases
Inflammation
Medical Genetics
Medical or Diagnostic Imaging
Medical Technology
Medical Treatment
Pancreas
Pathophysiology
Proteomics
Quality of Life Program
Registries
Stem Cells
Tumors
Ultrasonography
|
| Sponsor Reference No: |
PA-06-314 |
| Funding Type: |
Research
|
| COS Unique Id: |
99283 |
| Title: |
Drug Abuse Prevention Intervention Research (R21) |
| Sponsor: |
Department of Health and Human Services (HHS)
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
|
| Sponsor Type: |
Federal, U.S. |
| Deadline: |
June 16, 2008
|
| Deadline Note: |
This program will expire on September 8, 2008. |
| Amount Note: |
This program will use the R21 grant mechanism. The
total project period for an application submitted in response to this
funding opportunity may not exceed two years. Although the size of
award may vary with the scope of research proposed, it is expected that
applications will stay within the budgetary guidelines for an
exploratory/developmental project; direct costs are limited to $275,000
over an R21 two-year period. |
| Eligibility: |
Applications may be submitted by domestic and
foreign, for-profit or nonprofit organizations and public or private
institutions, such as universities, colleges, hospitals, and
laboratories; units of state and local governments; eligible agencies
of the federal government; faith-based or community-based
organizations; and units of state and local tribal governments. |
| Citizenship or Residency: |
Unrestricted
|
| Activity Location: |
Unrestricted
|
| Requirements: |
Small Business
Ph.D./M.D./Other Professional
Commercial
Government
Nonprofit
Academic Institution
|
| Abstract: |
The purpose of the National Institute on Drug
Abuse's (NIDA's) Prevention Research Branch (PRB) is to support a
developmentally grounded program of research on the prevention of the
initiation of drug use, progression to abuse and dependence, and
transmission of drug-related HIV infection. This research involves the
use of rigorous scientific methods to test theoretically derived
hypotheses to advance our understanding of the science of prevention
within diverse populations and settings. Studies that support this
purpose include
investigations of
- cognitive, behavioral, and social processes as they relate to the development of novel prevention approaches;
- the efficacy and effectiveness of newly developed or modified prevention programs;
-
the processes associated with the selection, adoption, adaptation,
implementation, sustainability, and cost effectiveness of science-based
interventions; and
- methodologies appropriate for studying complex aspects of prevention science. |
| Contact Name: |
Elizabeth B. Robertson, Ph.D., Chief |
| Contact Address: |
National Institute on Drug Abuse
Division of Epidemiology, Services and Prevention Research
Prevention Research Branch
6001 Executive Boulevard, Room 5160 |
| Contact City: |
Bethesda |
| Contact State: |
Maryland |
| Contact Zip: |
20892-9589 |
| Contact Country: |
United States |
| Contact Phone: |
+1 (301) 443-6504 |
| Contact Fax: |
+1 (301) 480-2542 |
| Contact Email: |
er52h@nih.gov |
| URL for more information: |
http://grants.nih.gov/grants/guide/pa-files/PA-06-317.html |
| Date Last Revised: |
March 3, 2008 |
| URL from COS to Bookmark this record: |
http://fundingopps.cos.com/cgi-bin/getRec?id=99283 |
| Keywords: |
AIDS (Substance Abuse)
Drug Abuse Prevention
Drug Abuse Treatment
Drugs or Drug Abuse
HIV
HIV Prevention
|
| Sponsor Reference No: |
PA-06-317 |
| Funding Type: |
Research
|
|
|
©2008, ProQuest LLC All rights reserved
|
|
